BV Pharmaceutical, Inc. (BVPI)

[originunknown]

B V Pharmaceutical Inc Announces Resignation of Art Bandenieks and Appointment of Leigh Lyons
Friday February 10, 6:36 pm ET

ALDERGROVE, BC--(MARKET WIRE)--Feb 10, 2006 -- B V Pharmaceutical Inc. (OTC BB:BVPI.OB - News) announces that Mr. Art Bandenieks has resigned as President, Secretary and Director of the Company. Effective this date Mr. Leigh Lyons of Bellingham, Washington will serve as President Secretary and Director of B V Pharmaceutical.

ADVERTISEMENT
Mr. Lyons brings to the Company 22 years of experience in the domestic and international oil and gas sector, specializing in general management, operations, strategic planning, acquisitions and project management. In addition to his new position with the company, Mr. Lyons serves as President and Director of Digital Ecosystems Corp. and Benem Ventures Inc. having assumed both positions in September 2005.

Prior to 2005 Mr. Lyons was Chief Operation Officer and Project Director for Gas TransBoliano S.A., a Shell/Enron controlled gas transmission company headquartered in Bolivia. Other positions held by Mr. Lyons include, President and Director of Can West Exploration Inc, a public company on the TSX, Vice President of Exploration and Production for Compania General de Combustibles S.A. in Buenos Aires, (a private company), and Vice President of Corporate Development for Global Natural Resources Inc., a company traded on the American stock exchange based out of Houston. Mr. Lyons received his Bachelor of Arts in Earth Science from the University of California, Santa Cruz in 1984 and is an Alumnus of the Harvard Business School having completed the Advanced Management Program in 2004.

Additionally B V Pharmaceutical is pleased to announce that Mr. Art Bandenieks has returned to the treasury 29 million shares. These shares have been bought back by the company for $29,000 USD.

Furthermore, the company wishes to announce that the common shares of B V Pharmaceutical, effective February 15, 2006 will be forward split on a 4-1 basis. Post-split there will be a total of 35,065,824 shares outstanding.

On behalf of the Board -- Lee Southern

This Press Release may contain, in addition to historical information, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on management's expectations and beliefs, and involve risks and uncertainties. These statements may involve known and unknown risks and uncertainties and other factors that may cause the actual results to be materially different from the results implied herein. Readers are cautioned not to place undue reliance on the forward-looking statements made in this Press Release.


Contact:

For further information contact the Company at
360-685 4200 (tel)
360 685 4222(fax)

B V Pharmaceutical Inc
2876-252nd Street
Aldergrove BC
V4W 2R2